Fluoxetine and Vitamin D3 Composition for Depigmentation Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for depigmentation disorders, such as vitiligo, often result in side effects and require high doses of fluoxetine or vitamin D derivatives, which can be toxic.
Innovation Solution
A composition combining fluoxetine with vitamin D3 or its derivatives, specifically calcipotriol, tacalcitol, and calcitriol, is used to treat depigmentation disorders, reducing toxicity and side effects while enhancing melanogenesis and tyrosinase activity in a dose-dependent manner.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of fluoxetine or vitamin D derivatives are used to treat depigmentation disorders, then treatment efficacy is improved, but toxicity and side effects increase
Solution Approach 1:
The patent combines fluoxetine and vitamin D derivatives into a single pharmaceutical composition for topical application. This merging of two active ingredients allows them to work synergistically to treat depigmentation disorders while using lower doses of each component, thereby reducing individual toxicity and side effects while maintaining or improving overall treatment efficacy.
Solution Approach 2:
The invention creates a composite pharmaceutical formulation containing both fluoxetine and vitamin D derivatives (such as calcipotriol, tacalcitol, or calcitriol) in specific concentrations. This composite material approach enables the drugs to complement each other's mechanisms of action - fluoxetine promoting melanocyte function and vitamin D derivatives regulating keratinocyte proliferation and differentiation - achieving better therapeutic outcomes with reduced dosing.
2Device complexity
If monotherapy with fluoxetine or vitamin D derivatives is used, then treatment simplicity is maintained, but treatment efficacy is limited
Solution Approach 1:
The patent merges fluoxetine and vitamin D derivatives into a single combined pharmaceutical composition, maintaining treatment simplicity by requiring only one application rather than multiple separate treatments. This unified formulation delivers both active ingredients simultaneously to the skin, allowing them to work synergistically to enhance melanogenesis and improve depigmentation disorders more effectively than either agent alone.
Data Source
Figure 1~4
Figure 5~8
Figure 9~12
AI summary
The present invention provides a composition, use of the composition in preparing drugs for treating and/or relieving depigmentation disorders, and a preparation comprising the composition. The composition comprises fluoxetine and vitamin D3 or derivatives of vitamin D3. In the composition, fluoxetine in combination with VD3 derivatives can improve melanogenesis. Compared with VD3 derivatives or fluoxetine when used alone, fluoxetine in combination with VD3 derivatives can not only improve the curative effect, but also reduce the dosage of VD3 derivatives or fluoxetine and the occurrence of toxic and side effects.